Age-related diseases frequently cause oxidative damage and inflammation that should be preventable, but plausible anti-oxidants and anti-inflammatory approaches have not proven useful. In particular, recent data with anti-oxidants like Vitamin E and NSAIDs, including the COX-2 inhibitors and naproxen, have raised concerns about both their chronic safety and efficacy. Because of its potent anti-carcinogenic activity, curcumin has already been through extensive pre-clinical toxicology and clinical testing and has a very favorable safety profile [1] and [13]. Because of its availability and low cost, coupled with preclinical data showing its potential for intervention at multiple sites in AD pathogenesis, curcumin is now in clinical trials in mild to moderate AD patients under an FDA approved IND by the UCLA Alzheimer Center. Omega-3 fatty acids have an even stronger safety profile, a long history of use and proven health benefits for CVD, yet typical Western diets have
Age-related diseases frequently cause oxidative damage and inflammation that should be preventable, but plausible anti-oxidants and anti-inflammatory approaches have not proven useful. In particular, recent data with anti-oxidants like Vitamin E and NSAIDs, including the COX-2 inhibitors and naproxen, have raised concerns about both their chronic safety and efficacy. Because of its potent anti-carcinogenic activity, curcumin has already been through extensive pre-clinical toxicology and clinical testing and has a very favorable safety profile [1] and [13]. Because of its availability and low cost, coupled with preclinical data showing its potential for intervention at multiple sites in AD pathogenesis, curcumin is now in clinical trials in mild to moderate AD patients under an FDA approved IND by the UCLA Alzheimer Center. Omega-3 fatty acids have an even stronger safety profile, a long history of use and proven health benefits for CVD, yet typical Western diets have <30% of the roughly 200–300 mg of DHA recommended by expert panels. Epidemiology shows risk reduction of 60% associated with modest increases in DHA intake or plasma levels. DHA works well in slowing AD pathogenesis in mice with a human AD gene and is safe enough to include in infant formula. It should be a strong candidate for use in primary prevention.
การแปล กรุณารอสักครู่..
